AstraZeneca (LON:AZN) Receives “Overweight” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their overweight rating on shares of AstraZeneca (LON:AZN) in a report issued on Monday, Marketbeat.com reports.

A number of other research analysts have also commented on AZN. Jefferies Financial Group increased their price objective on AstraZeneca from GBX 71 ($0.94) to GBX 74 ($0.98) and gave the company a hold rating in a research report on Tuesday, July 2nd. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research note on Thursday, July 25th. Berenberg Bank restated a buy rating and issued a £150 ($198.15) price objective on shares of AstraZeneca in a report on Monday, September 2nd. Deutsche Bank Aktiengesellschaft reiterated a hold rating and set a £110 ($145.31) target price on shares of AstraZeneca in a research report on Tuesday, September 3rd. Finally, Citigroup reiterated a buy rating on shares of AstraZeneca in a report on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of £105.53 ($139.41).

AstraZeneca Trading Up 0.4 %

AZN opened at £118.98 ($157.17) on Monday. AstraZeneca has a 1-year low of GBX 9,461 ($124.98) and a 1-year high of £133.88 ($176.86). The firm has a 50-day moving average price of £125.74 and a two-hundred day moving average price of £119.31. The stock has a market capitalization of £184.42 billion, a PE ratio of 3,813.46, a PEG ratio of 0.93 and a beta of 0.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.

AstraZeneca Cuts Dividend

The business also recently announced a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were issued a dividend of GBX 77.60 ($1.03) per share. The ex-dividend date was Thursday, August 8th. This represents a yield of 0.64%. AstraZeneca’s dividend payout ratio (DPR) is currently 7,500.00%.

Insider Activity

In related news, insider Michel Demare acquired 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were acquired at an average cost of GBX 118 ($1.56) per share, for a total transaction of £2,360 ($3,117.57). Corporate insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.